Cell encapsulation technology as a therapeutic strategy for CNS malignancies.
Cell encapsulation technology as a therapeutic strategy for CNS malignancies.
复制标题
细胞封装技术作为中枢神经系统恶性肿瘤的治疗策略。
作者：
T. Visted;R. Bjerkvig;P. Enger
使用病毒载体的基因治疗迄今未能揭示其明确的临床用途。细胞包封技术代表了一种将生物活性化合物递送至肿瘤的替代性非病毒方法。该策略涉及使用基因工程生产细胞，其分泌具有治疗潜力的蛋白质。这些细胞被包裹在一种免疫隔离材料中，使它们适合移植。胶囊或生物反应器允许释放重组蛋白，这些蛋白可能在肿瘤微环境中发挥作用。在过去的几十年中，在包括用于宏包封和微包封的装置的包封技术的开发方面已经取得了重大进展。藻酸多糖是最常用的细胞包封材料，并且被各种组织很好地耐受。已经在动物和人类中封装和植入了广泛的细胞和组织，表明这种方法对于研究和医疗目的的普遍适用性，包括CNS恶性肿瘤。胶质瘤最常在切除部位复发。为了提供局部和持续的药物递送，可以将生物反应器植入脑实质或脑室系统中。肿瘤的基因和表型谱的综合分析（基因组学和蛋白质组学）的发展可能为选择生物反应器和重组蛋白的最佳组合用于治疗提供新的和重要的指导方针。
Gene therapy using viral vectors has to date failed to reveal its definitive clinical usefulness. Cell encapsulation technology represents an alternative, nonviral approach for the delivery of biologically active compounds to tumors. This strategy involves the use of genetically engineered producer cells that secrete a protein with therapeutic potential. The cells are encapsulated in an immunoisolating material that makes them suitable for transplantation. The capsules, or bioreactors, permit the release of recombinant proteins that may assert their effects in the tumor microenvironment. During the last decades, there has been significant progress in the development of encapsulation technologies that comprise devices for both macro- and microencapsulation. The polysaccharide alginate is the most commonly used material for cell encapsulation and is well tolerated by various tissues. A wide spectrum of cells and tissues has been encapsulated and implanted, both in animals and humans, indicating the general applicability of this approach for both research and medical purposes, including CNS malignancies. Gliomas most frequently recur at the resection site. To provide local and sustained drug delivery, the bioreactors can be implanted in the brain parenchyma or in the ventricular system. The development of comprehensive analyses of geno- and phenotypic profiles of a tumor (genomics and proteomics) may provide new and important guidelines for choosing the optimal combination of bioreactors and recombinant proteins for therapeutic use.
影响因子：
37.8
作者：
Laham, RJ;Sellke, FW;Simons, M
通讯作者：
Simons, M
聚合物封装神经递质分泌细胞的移植：封装技术的效果。
DOI：
10.1115/1.2891231
发表时间：
1991
期刊：
Journal of biomechanical engineering
影响因子：
--
作者：
Aebischer,P;Winn,SR;Tresco,PA;Jaeger,CB;Greene,LA
通讯作者：
Greene,LA